Close

UPDATE: Cowen Upgrades Sarepta Therapeutic (SRPT) to Outperform

Go back to UPDATE: Cowen Upgrades Sarepta Therapeutic (SRPT) to Outperform

Sarepta Therapeutics (SRPT) Shares on Watch Amid Chatter of Secondary Stock Offering

September 20, 2016 3:09 PM EDT

Sarepta Therapeutics (Nasdaq: SRPT) shares are on watch amid speculation of an impending secondary stock offering. No official announcement has been made yet.

... More

Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer

September 20, 2016 1:18 PM EDT

Oppenheimer analyst Michelle Gilson notes US Patent and Trademark Office ruled in favor of Sarepta (NASDAQ: SRPT) for Patents 7,960,541 and 7,807,816 in its patent interference proceeding (interference number 106,008).

Gilson notes these cover composition of matter for eteplirsen, giving the Sarepta freedom to operate... More

Sarepta Therapeutic (SRPT) PT Raised to $66 at Wedbush

September 20, 2016 7:21 AM EDT

Wedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $66.00 (from $36.00) after the FDA approved eteplirsen.

Behanna commented, "In line with our expectations after FDA asked for new data, eteplirsen has received accelerated... More

FDA Approves Sarepta Therapeutics' (SRPT) Eteplirsen

September 19, 2016 9:52 AM EDT

(Updated - September 19, 2016 9:56 AM EDT)

The U.S. Food and Drug Administration today approved Sarepta Therapeutics' (Nasdaq: SRPT) Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with DMD.

Patients with a particular type of Duchenne muscular dystrophy will now have access to an approved treatment for this rare and devastating disease, said Janet Woodcock, M.D., director of the... More

Sarepta Therapeutics (SRPT) Granted FDA Accelerated Approval for Eteplirsen

September 19, 2016 9:51 AM EDT

Sarepta Therapeutics (NASDAQ: SRPT) surges higher on FDA approval for eteplirsen

Letter from FDA

... More